The BIOSECURE Act is now law. Here’s what it means for you.
Signed into law in December 2025 as part of the FY 2026 National Defense Authorization Act, the BIOSECURE Act requires U.S. companies to transition away from designated biotechnology companies of concern. For pharma, this means re-evaluating your entire CDMO and supplier network.
Read the Full Text of H.R. 8333 →What You Need to Know
What It Does
The BIOSECURE Act prohibits U.S. government agencies from contracting with companies that use biotechnology equipment or services from designated companies of concern, primarily targeting entities with ties to foreign adversaries.
Who It Affects
Any pharmaceutical, biotech, or life sciences company that works with designated CDMOs or suppliers is impacted. If you receive federal funding, hold government contracts, or plan to in the future, compliance is mandatory.
What’s at Stake
Non-compliance means losing eligibility for federal contracts and funding. Companies must identify affected relationships, plan transitions, and execute technology transfers to compliant partners within mandated timelines.
Key Dates & Deadlines
The BIOSECURE Act includes a phased implementation timeline. Companies should begin planning transitions immediately to avoid disruptions.
Signed Into Law
The BIOSECURE Act was signed as part of the FY 2026 NDAA, establishing the legal framework for restricting contracts with designated biotechnology companies of concern.
Designation & Assessment Period
Federal agencies begin designating biotechnology companies of concern. Companies should audit their supply chains and identify relationships that may fall under the Act’s scope.
Transition Window
Companies must complete transitions away from designated entities. This includes executing technology transfers, qualifying new CDMOs, and validating manufacturing processes at compliant facilities.
Full Enforcement
Federal agencies are prohibited from entering into contracts with companies still relying on designated biotechnology companies of concern. Non-compliant companies lose access to government funding and contracts.
How TransferPilot Helps
BIOSECURE compliance isn’t just a legal checkbox. It requires executing complex technology transfers under tight timelines. That’s exactly what TransferPilot was built for.
Supply Chain Audit
Use our AI-powered document intelligence to rapidly analyze your existing CDMO and supplier relationships, identifying which partnerships fall under the BIOSECURE Act’s scope and which require immediate action.
Gap Analysis & CDMO Matching
Our gap analysis engine compares your technical requirements against compliant CDMO capabilities, identifying the best-fit partners and flagging potential gaps before you commit to a transition.
Accelerated Tech Transfer
TransferPilot’s unified workspace streamlines the transfer process, bringing sending sites, receiving sites, and cross-functional teams together with real-time task tracking and automated document analysis.
Compliance Tracking
Stay on top of BIOSECURE deadlines and requirements with built-in compliance gates, automated status updates, and audit-ready documentation that proves your transition is on track.
Start Your BIOSECURE Transition Today
Don’t wait for enforcement deadlines. Get ahead of the curve with TransferPilot.
Request a Demo →